Multiple Myeloma Management

0.0 89.88MB 0 Free

Category_6020(29086)

Version 1.0 Updated 0001-01-01 Developer UMA MLG, LLC

GetAppNow

Details
InAppPurchase
AppInsight

Description

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.

CategoryLabel医疗(29086) VersionLabel1.0 BundleId: com.mlg.mmar DeveloperLabelUMA MLG, LLC LastUpdatedLabel0001-01-01

InAppPurchase

InAppPurchase_ItemsCount InAppPurchase_CurrenciesCount CNY

1 中国

InAppPurchase_DefaultItemName

¥ 0 CNY

InAppPurchase_Sequence	InAppPurchase_Name	InAppPurchase_Price	InAppPurchase_Currency	InAppPurchase_Region
1	InAppPurchase_DefaultItemName	¥ 0	CNY	中国

Multiple Myeloma Management

Description

InAppPurchase_DefaultItemName

HotRecommend